Skip to main content
. 2019 Dec 30;75(2):477–482. doi: 10.1161/HYPERTENSIONAHA.119.13642

Table 2.

SBP and DBP at 3 Months in the Placebo Group and in the Combined Canakinumab Treatment Group Stratified by Achieved Levels of hsCRP and IL-6 Above or Below the On-Treatment Study Median

graphic file with name hyp-75-477-g003.jpg